203192-01-2

Usage

Uses

Used in Molecular Biology Research:
1,1'-[4,4'-(butane-1,4-diyl)bis(1,4-phenylene)]bis(methylene)bis(4-(dimethylamino)pyridinium) dibromide is used as a fluorescent dye for protein labeling due to its high water solubility and lipophilic nature. This allows for effective penetration of cell membranes and precise labeling of proteins, which is crucial for various molecular biology applications, including the study of protein interactions, localization, and dynamics within cells.
Used in Drug Delivery Systems:
In the pharmaceutical industry, 1,1'-[4,4'-(butane-1,4-diyl)bis(1,4-phenylene)]bis(methylene)bis(4-(dimethylamino)pyridinium) dibromide can be utilized as a component in drug delivery systems. Its lipophilic properties and ability to penetrate cell membranes make it a promising candidate for enhancing the delivery of therapeutic agents, potentially improving their bioavailability and therapeutic outcomes.
Used in Diagnostic Imaging:
1,1'-[4,4'-(butane-1,4-diyl)bis(1,4-phenylene)]bis(methylene)bis(4-(dimethylamino)pyridinium) dibromide, due to its fluorescent properties, can be employed in diagnostic imaging applications. It can be used to label biological molecules for tracking and visualizing their distribution within organisms, aiding in the diagnosis and monitoring of various diseases and conditions.
Used in Environmental Research:
In environmental science, 1,1'-[4,4'-(butane-1,4-diyl)bis(1,4-phenylene)]bis(methylene)bis(4-(dimethylamino)pyridinium) dibromide can be applied as a tracer compound for studying the behavior of pollutants or contaminants in various ecosystems. Its fluorescent properties allow for the tracking and analysis of these substances, providing valuable insights into their environmental impact and potential risks.

Upstream product

• 886-65-7 trans,trans-1,4-Diphenyl-1,3-butadiene 
• 1083-56-3 1,4-diphenylbutane 
• 1122-58-3 dmap 
• 61390-67-8 1,4-bis[4-(bromomethyl)phenyl]butane 

Relevant academic research and scientific papers

Quantitative structure-activity relationships for a series of symmetrical bisquaternary anticancer compounds

56 biscationic dibromides with distinct polar heads [bis(4-substituted)pyridinium, bis(4-aminoquinolinium), bisquinolinium, and bisisoquinolinium moieties] and several spacers between the two charged nitrogen atoms were synthesised. This oriented synthesis produced 45 inhibitors of choline kinase with antitumour activity against the HT-29 cell line. In an attempt to understand the antiproliferative activity, a quantitative structure-activity relationship was developed. The unknown σR and σR+ descriptors for the diallylamino, pyrrolidino, piperidino and perhydroazepino groups and σR for the N-methylanilino moiety, were estimated by 13C NMR spectroscopy in a simple, fast and reproducible manner. The electron characteristic of the substituent at position 4 of the heterocycle and the theoretical lipophilic character of the whole molecule were found to significantly affect the antitumour activity. 1,1′-[Ethylenebis(benzene-1,4-diylmethylene)]bis[4-(N-methylanilino) pyridinium] dibromide is the most active compound of the series so far described and shows a reasonable agreement between predicted and observed antiproliferative data (predicted pIC50=6.50, experimental pIC50=6.46).

DIAGNOSING AND TREATING CANCER

The invention relates to compositions and methods for diagnosing as well as treating cancer diseases associated with choline kinase (ChoK). Specifically, the invention relates to a composition comprising an intrinsically fluorescent choline kinase (ChoK)

Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: A systematic investigation of the influence of linker and cationic heads over affinity and selectivity

A molecular library of quaternary ammonium salts (QASs), mainly composed of symmetrical bis-quaternary heterocyclic bromides exhibiting choline kinase (ChoK) inhibitory activity, were evaluated for their ability to inhibit acetyl- and butyrylcholinesterase (AChE and BChE, respectively). The molecular framework of QASs consisted of two positively charged heteroaromatic (pyridinium or quinolinium) or sterically hindered aliphatic (quinuclidinium) nitrogen rings kept at an appropriate distance by lipophilic rigid or semirigid linkers. Many homodimeric QASs showed AChE and BChE inhibitory potency in the nanomolar range along with a low enzymatic selectivity. Computational studies on AChE, BChE, and ChoK allowed identification of the key molecular determinants for high affinity and selectivity over either one of the three enzymes and guided the design of a hybrid bis-QAS (56) exhibiting the highest AChE affinity (IC50 = 15 nM) and selectivity over BChE and ChoK (SI = 50 and 562, respectively) and a promising pharmacological potential in myasthenia gravis and neuromuscular blockade.